Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for autoimmune and neurodegenerative diseases. The company is headquartered in South San Francisco, California.
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-202.89M |
| Operating Margin | 0.00% |
| Return on Equity | -87.60% |
| Return on Assets | -45.30% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $1.26 |
| Price-to-Book | 4.25 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | -2.47 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $163.84M |
| Float | $130.11M |
| % Insiders | 0.47% |
| % Institutions | 102.64% |
Volatility is currently expanding